IndustryCompany release

AtriCure third-quarter revenue rises 15% to $154.5M as company returns to profit

🇺🇸 AtriCure, Inc. (ATRC) · Tue 03 Nov 2026

The cardiac surgery device maker reported net income of $4.1 million for the quarter and issued full-year 2026 revenue guidance of about $606–610 million.

AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million on 3 November, a rise of 15.0% on the same period a year earlier. The company posted net income of $4.1 million for the quarter.

According to the company's summary of the results, growth was driven by the cryoSPHERE MAX pain probe, the EnCompass clamp and the AtriClip left atrial appendage management devices.

Sales of minimally invasive ablation products declined in the quarter. AtriCure attributed this to physicians moving towards pulsed field ablation (PFA) catheters.

For the full year 2026, the company set revenue guidance at about $606–610 million and adjusted EBITDA guidance at $91–94 million. The summary does not provide further detail on the assumptions behind the outlook.

What it means for your team

  • Market-access teams should note the reported shift from minimally invasive ablation to PFA catheters, which shows how quickly procedural preferences can change a product mix.
  • Pain management and appendage management products were the named growth contributors, so those lines may attract more attention from hospital purchasing and evidence teams.
  • Regulatory and quality teams tracking the company should treat the updated guidance as a financial indicator only; the summary contains no regulatory or safety information.

Company's press release (SEC filing): AtriCure, Inc. ↗

Article written by VigiEye from the official source (AtriCure, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →